Response to Comments: Biomarker Testing (Prior to Initial Biopsy) for Prostate Cancer Diagnosis

This document is a response to comments regarding the Biomarker Testing (Prior to Initial Biopsy) for Prostate Cancer Diagnosis LCD and does not itself specify clinical coverage criteria. The official notice period began on October 10, 2019, and the final LCD determination became effective December 1, 2019. Stakeholder comments were solicited as part of LCD development.

"Official notice period for the final LCD began on 2019-10-10 and the final determination became effective on 2019-12-01."

Sign up to see full coverage criteria, indications, and limitations.